Pharmacokinetics of moclobemide after single and multiple oral dosing with 150 milligrams 3 times daily for 15 days

  title={Pharmacokinetics of moclobemide after single and multiple oral dosing with 150 milligrams 3 times daily for 15 days},
  author={Theodor W. Guentert and Geoffrey T Tucker and Adrienne Korn and J. P. Pfefen and P. Haefelfinger and M. P. Schoerlin},
  journal={Acta Psychiatrica Scandinavica},
This study was undertaken to determine the absolute bioavailability and steady‐state concentrations of moclobemide after doses of 150 mg. In 14 healthy human volunteers, no differences in tmax, t1/2β, Cl/F, Cmax and AUC were found between a single oral dose of 100 mg and one of 150 mg. The mean absolute oral availability was 0.66 and 0.69 respectively. Plasma concentration profiles of moclobemide on repeated dosing with 150 mg 3 times daily for 15 days were essentially superimposable, although… Expand
Evaluation of Single‐Point Sampling Strategies for the Estimation of Moclobemide Exposure in Depressive Patients
As the most reliable surrogate for moclobemide systemic exposure, concentrations at 4 and 6 hours should be used instead of predose trough concentrations as an indicator of between‐patient variability and a guide for dose adjustments in specific clinical situations. Expand
Pharmacokinetics of Moclobemide in Male, Virgin Female, Pregnant and Nursing Rats
Moclobemide as well as the N‐oxide and lactam metabolites were found in the amniotic fluid suggesting that moclobamide is capable of crossing the placental barrier. Expand
Comparison of the pharmacokinetics of moclobemide in poor and efficient metabolizers of debrisoquine
No deviations of moclobemide pharmacokinetics should be expected in poor metabolizers of debrisoquine compared with normal metabolizers, and this was true for both single and multiple dosing. Expand
Monoamine oxidase-A: pharmacodynamics in humans of moclobemide, a reversible and selective inhibitor.
In contrast to DHPG, 5HIAA formation was only partially suppressed by moclobemide, suggesting the existence of 5HiaA formation pathways independent of those inhibitable by mClobemides, and a physiological pharmacokinetic-pharmacodynamic model was used to describe MAO-A inhibition as reflected in the alterations of monoamine metabolites. Expand
Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: A panel study *
A combined mephenytoin, sparteine, and caffeine test performed before, during, and after multiple dosing of moclobemide showed changes in the metabolic indexes compatible with a reversible inhibition of oxidation by way of the corresponding CYP enzymes—CYP2C19, CYP2D6, and CYP1A2—during moclOBemide treatment. Expand
Moclobemide monotherapy vs. combined therapy with valproic acid or carbamazepine in depressive patients: a pharmacokinetic interaction study.
VPA does not significantly affect PK or metabolism ofMCB, whereas CBZ time-dependently decreases MCB exposure, probably by inducing metabolism of MCB and its major plasma metabolite. Expand
Moclobemide treatment causes a substantial rise in the sparteine metabolic ratio. Danish University Antidepressant Group.
During moclobemide treatment the sparteine MR rose substantially by a factor of 1-103 (median 4.7), and two EM became phenotypically PM, and in the PM subjects as well as in one EM patient on cimetidine during both tests, no change in spartenine MR occurred. Expand
Moclobemide poisoning: toxicokinetics and occurrence of serotonin toxicity.
Moclobemide overdose in combination with a serotonergic agent (even in normal therapeutic doses) can cause severe serotonin toxicity, and the elimination half-life is prolonged by two to four times in overdose, compared with that found in healthy volunteers given therapeutic doses. Expand
Individual Variation in First-Pass Metabolism
  • Y. Tam
  • Biology, Medicine
  • Clinical pharmacokinetics
  • 1993
Of various factors considered, age and gender make the least evident contributions, whereas genetic polymorphism, enzymatic changes due to induction or inhibition, and the effects of food are major contributors to the variability in first-pass metabolism. Expand
Moclobemide twice daily in the treatment of major depressive episode: a double-blind, multicenter comparison with different three-times-daily dosage schedules.
Tolerability was rated "good" or "excellent" in 94% of patients, and there was no appreciable change in vital signs in any of the treatment groups, suggesting that twice-daily moclobemide 150 mg b.i.d. is the optimal initial schedule for treatment of depression. Expand


Disposition kinetics of moclobemide, a monoamine oxidase‐A enzyme inhibitor: Single and multiple dosing in normal subjects
The absorption and disposition kinetics of moclobemide (Ro 11‐1163), a new reversible and preferential monoamine oxidase‐A enzyme inhibitor, were examined in 12 normal male subjects, finding a reduced metabolic, presumably hepatic, clearance that may be the result of self‐inhibition or metabolite inhibition of mClobemid clearance. Expand
Determination of the new monoamine oxidase inhibitor moclobemide and three of its metabolites in biological fluids by high-performance liquid chromatography.
A sensitive high-performance liquid chromatographic method has been developed for the determination of moclobemide and three of its metabolites in plasma and urine and non-ideal interactions of the basic compounds and the N-oxide metabolite occurred with many other reversed-phase materials. Expand